Phase III Trial of Jincaopian Tablets for Treating Chronic Pelvic Pain After Pelvic Inflammatory Disease in Women Aged 18 to 50

What this Trial Is About

Researchers are evaluating the efficacy and safety of Jincaopian Tablets for treating chronic pelvic pain in women who have had pelvic inflammatory disease. This phase III clinical trial aims to address the significant burden of chronic pelvic pain, a common complication following pelvic inflammatory disease, by comparing Jincaopian Tablets to a placebo in a well-controlled study environment. Participants are randomly assigned in a 21 ratio to receive either Jincaopian Tablets or a placebo. Those in the Jincaopian group take 0.6 grams daily for 12 weeks, while the placebo group receives an identical regimen. After completing the treatment period, all participants enter a 4-week follow-up period to assess ongoing effects. During the study, researchers will monitor pain disappearance rates at 12 weeks as the primary outcome. Secondary measures include pain scores over time, quality of life assessments, and evaluations of physical signs related to pain. Safety is closely monitored through reports of adverse events. Participants will be regularly assessed throughout the 16-week total study duration to understand treatment impact and safety.

A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease